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ABSTRACT
Aims/Introduction: Previous studies have reported osteoporosis measured by dual-
energy X-ray absorptiometry in younger patients with type 1 diabetes. Limitations of 2-D
imaging, however, limit the precision of dual-energy X-ray absorptiometry for the
measurement of bone mineral density and bone strength.
Materials and Methods: Three-dimensional quantitative computed tomography was
used to calculate volumetric-bone mineral density (vBMD) and strength in femoral bone
subfractions. A total of 17 male type 1 diabetes patients and 18 sex-matched healthy
controls aged from 18 to 49 years were investigated in the present cross-sectional study.
Patients with overt nephropathy were excluded.
Results: Type 1 diabetes patients had significantly lower cortical vBMD in the femoral
neck, and significantly lower total vBMD, cortical thickness and cortical cross-sectional area
(cortical CSA) in the intertrochanter. Bone strength estimated by the buckling ratio (an
index of cortical instability) of the intertrochanter was significantly higher in type 1 diabe-
tes patients. The following serum bone markers were comparable between the two
groups: bone-specific alkaline phosphatase, N-terminal propeptide of type 1 procollagen,
osteocalcin, pentosidine and homocysteine. Serum insulin-like growth factor-1 values were
significantly lower in the type 1 diabetes patients than in controls. Serum insulin-like
growth factor-1values were positively correlated with serum bone formation markers, and
the total vBMD of the femoral neck and lumbar spine in type 1 diabetes patients.
Conclusions: The present study is the first investigation by quantitative computed
tomography measurement to show cortical instability and lower vBMD in the intertro-
chanter of young and middle-aged type 1 diabetes patients. Low insulin-like growth
factor-1 might be a causative factor for osteoporosis in type 1 diabetes.
INTRODUCTION
Many studies by dual-energy X-ray absorptiometry (DXA) have
shown an elevated risk of decreased bone mineral density
(BMD) in children with type 1 diabetes1–4. Other studies,
meanwhile, have found no signiﬁcant differences in BMD at
the lumbar spine or proximal femur between patients with
type 1 diabetes and controls5,6.
DXA is a two-dimensional imaging modality with limited
precision in the measurement of BMD. DXA scans are also of
limited use for longitudinal studies, as the planar technique is
unsuitable for evaluating volumetric-BMD (vBMD) or tracking
changes in body and skeletal size during growth7,8. DXA also
fails to differentiate between cortical and trabecular BMD, or to
measure cross-sectional geometry or biomechanical parameters,
such as the cross-sectional moment of inertia (CSMI), section
modulus (SM; a geometric index of bending stress) or buckling
ratio (BR; an index of cortical instability).
Quantitative computed tomography (QCT), in contrast, can
take 3-D measurements of the vBMD independently in cortical
and trabecular bone compartments, and assess both cross-sec-Received 27 August 2014; revised 30 March 2015; accepted 31 March 2015
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tional geometry and biomechanical parameters. Researchers are
taking advantage of these capabilities of QCT in a growing
number of clinical studies on topics such as the effects of drug
therapy on hip structure9–13, mechanical loading in the proxi-
mal femur, and the association of hip fractures with femoral
strength and bone structure14–18.
Peripheral QCT studies of the radius or tibia have shown a
lower vBMD in pediatric and adolescent patients with type 1
diabetes19–21. Yet to our knowledge, QCT has not been previ-
ously used to investigate the vBMD, cross-sectional geometry,
or biomechanical parameters of femoral bone subfractions or
the vBMD of the lumbar spine in young and middle-aged
patients with type 1 diabetes.
Insulin-like growth factor-1 (IGF-1) is a growth-promoting
polypeptide essential for normal growth and development.
IGF-1 administration increases bone turnover and BMD in
both humans and experimental animals22–24. Dysregulation of
the growth hormone/IGF-1 axis is well-recognized in patients
with type 1 diabetes. Many studies have shown that the low
serum IGF-1 values in pediatric and adult patients with
type 1 diabetes might contribute to the pathogenesis of
reduced BMD25,26.
The aims of the present study were to determine the vBMD,
cross-sectional geometry, and biomechanical parameters of fem-
oral bone subfractions and the vBMD of the lumbar spine by
QCT, and to elucidate the relationships between bone measure-
ments and IGF-1values, in young and middle-aged patients
with type 1 diabetes.
MATERIALS AND METHODS
Materials
A total of 17 consecutive male patients with type 1 diabetes
and 18 sex-matched controls were enrolled in the present
cross-sectional study. All of the patients were observed regularly
at the Showa University Hospital (Tokyo, Japan), and met the
following criteria: (i) aged 18–49 years; (ii) duration of diabetes
of at least 3 months; (iii) no evidence of overt nephropathy
(urine albumin-to-creatinine ratio >300 mg/g creatinine or
eGFR <60 mL/min/1.73 m2); (iv) no evidence of pre-prolifera-
tive diabetic retinopathy or proliferative diabetic retinopathy;
(v) no chronic disease apart from positive thyroid antibodies
with euthyroid status; and (vi) no restriction of physical activity.
None of the participants were taking calcium preparations or
medications or hormones known to affect bone metabolism.
Diabetic retinopathy was graded as simple, pre-proliferative or
proliferative retinopathy by ophthalmologists.
Healthy controls were recruited to serve as controls for
patient groups from our medical staff who were interested in
the status of their bone and accepted our study design. Possible
side-effects of X-ray exposure with the radiation dose of
approximately equal to abdomen and pelvic computed tomog-
raphy (CT) were explained. All participants provided written
informed consent, and the study was approved by the ethics
committee of the Showa University School of Medicine.
Background
Bodyweight was measured with digital scales. Body mass index
(BMI) was calculated as bodyweight (kg) / height2 (m2). Physi-
cal activity (1. exercise every day; 2. exercise two or three times
a week; 3. never exercise) and calcium intake were evaluated by
questionnaire. Smoking history and alcohol intake were evalu-
ated in each group.
Biochemical Measurements
Blood samples were obtained from all participants in a non-
fasting state and quickly stored at -80°C. Serum levels of total
protein, albumin, alkaline phosphatase, total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein choles-
terol, calcium, magnesium and phosphorus were measured in
all participants with an autoanalyzer in our hospital. Plasma
levels of intact parathyroid hormone and serum IGF-1 were
measured by chemiluminescent enzyme immunoassay and im-
munoradiometric assay, respectively. The Z-score of the serum
IGF-1 measurement was calculated from the LMS method,
using values appropriate for the age and sex27.
Serum levels of the following bone metabolic and quality
markers were measured: bone-speciﬁc alkaline phosphatase,
osteocalcin, N-propeptide of type I collagen, tartrate-resistant
acid phosphatase type 5 protein, cross-linked N-telopeptide of
type I collagen, pentosidine and homocysteine. The following
methods were used to carry out the measurements: bone-spe-
ciﬁc alkaline phosphatase, by chemiluminescent enzyme immu-
noassay; osteocalcin, by immunoradiometric assay; intact N-
propeptide of type I collagen, by double antibody-radio immu-
noassay; tartrate-resistant acid phosphatase type 5 protein and
serum-N-telopeptide of type I collagen, by enzyme immunoas-
say; pentosidine, by enzyme-linked immunosorbent assay; and
homocysteine, by high-performance liquid chromatography.
The value for glycated hemoglobin (HbA1c; %) in the present
study was estimated as a National Glycohemoglobin Standardi-
zation Program-equivalent value (%) calculated by the following
formula: HbA1c (%) = HbA1c (Japan Diabetes Society [JDS])
(%) + 0.4%28.
CT Data Acquisition
CT data were acquired with a SOMATOM Deﬁnition AS+
multidetector-row CT scanner (Siemens, AG, Forchheim,
Germany) using predeﬁned scanning conditions (X-ray energy,
120 kV; X-ray current, 200 mA; rotation speed, 1.0 s/rot; beam
pitch, 0.9) and predeﬁned reconstruction parameters. The CT
values were converted to a scale of bone mineral density using
a calibration phantom (Mindways, Austin, TX, USA) placed
underneath the patients during the scans.
Patient Position for CT Scanning
The participants were scanned in a supine position. The
calibration phantom was placed directly beneath the participant
in a position covering the region from the top of the lumbar
spine (L1) to 2 cm below the bottom of the lesser trochanter.
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Analysis of vBMD and bone geometry obtained by CT
The vBMD of the lumbar spine (L2, 3, 4 and L2-4), and the
vBMD and bone geometry of the proximal femur were ana-
lyzed using QCT-Pro software v4.1.3 with the QCT-Pro Bone
Investigational Toolkit v2.0 (BIT; Mindways Software, Austin,
TX, USA). The cross-sectional femoral neck data were based
on the geometrical axis. The total vBMD, cortical vBMD, corti-
cal perimeter, cortical thickness, total cross-sectional area (CSA)
and cortical CSA were also calculated for the femoral bone sub-
fractions (femoral neck, intertrochanter and femoral shaft).
These parameters could not be calculated for the femoral shaft
in some of the cases (2 patients with type 1 diabetes and 8
controls), however, as a 2-cm distance could not be maintained
below the bottom of the lesser trochanter when these partici-
pants were scanned.
Biomechanical Parameters of the Femoral Neck,
Intertrochanter and Femoral Shaft
The CSMI, SM, and BR of the femoral neck, intertrochanter
and femoral shaft were measured. The CSMI is deﬁned as an
integration of the product of the incremental cross-sectional
area and the square of its distance from the center of mass
(centroid). The SM, the ratio of CSMI to the maximal distance
of the material from the centroid, is directly related to the
strength with respect to a corresponding bending stress. BR,
the maximal distance from the centroid divided by the average
cortical thickness, is used to estimate the instability of the cor-
tex in thin-walled regions subject to local compressive stress12.
Quality Control Procedures
To adjust for longitudinal changes of the detector, quality
assurance scans were carried out with a calibration phantom
every 3 months. Quality assurance measurements were evalu-
ated according to the QCT-Pro quality assurance guide from
Mindways. The reproducibility (% coefﬁcient of variation) of
the analysis by the QCT PRO program was calculated using
ﬁve repeated analyses, each with visual matching, from the CT
data sets of 10 healthy participants without visual artifacts. The
QCT parameter values were as follows: vBMD 1.74%, cortical
vBMD 1.70%, cortical thickness 2.29%, cortical perimeter
3.19%, total CSA 5.49%, cortical CSA 5.54%, CSMI 7.02%, SM
8.07%, BR 5.89% and total vBMD (spine) 0.42%.
Statistical Analysis
Data were analyzed using Stat Flex Ver.6 (Artech, Tokyo,
Japan). The Student’s t-test was used to determine the signiﬁ-
cance of differences between the groups. The Mann–Whitney
U-test and v2-tests were used to determine differences between
patients with type 1 diabetes and controls with respect to phys-
ical activity and current smoking, respectively. Correlations
were based on Pearson’s correlation coefﬁcient. All values
calculated in the analysis were two-sided, and none were
adjusted for multiple testing. P-values of <0.05 were considered
statistically signiﬁcant.
RESULTS
Table 1 shows the clinical characteristics of the study partici-
pants. The mean age of patients with type 1 diabetes was
38.2 – 7.2 years (range 19–48 years). The mean age at onset
and the duration of diabetes were 22.6 – 9.9 years (range 1–
39 years) and 15.6 – 8.6 years (range 0–35 years), respectively.
The bodyweight, height and BMI were similar between the two
groups. Metabolic control was moderate to acceptable in most
patients, with a mean HbA1c of 7.4% (range 6.4–10.3%). A
total of 16 patients were receiving multiple injections (4–5
daily) of rapid-acting insulin-analogs and long-acting basal
insulin, and one patient was receiving a continuous subcutane-
ous infusion of insulin. The mean daily insulin dose was
0.83 – 0.17 U/kg/day. Two patients (12%) had simple retinopa-
thy. The mean urine albumin-to-creatinine ratio was 11.2
– 13.8 mg/g (range 2.5–60.9 mg/g) creatinine. A total of 16
patients (94%) had normoalbuminuria and one patient (6%)
had microalbuminuria.
Physical activity, current smoking and alcohol intake were
similar between the two groups.
Table 1 | Clinical characteristics of type 1 diabetes patients and
controls
Type 1
diabetes
patients
(n = 17)
Controls
(n = 18)
P
Age (years) 38.2 – 7.2 35.7 – 5.6 0.27
Age at onset
(years)
22.6 – 9.9 – –
Duration of
diabetes (years)
15.6 – 8.6 – –
Bodyweight (kg) 67.7 – 7.9 71.3 – 7.6 0.18
Height (cm) 171.6 – 6.2 174.1 – 5.0 0.19
BMI (kg/m2) 23.0 – 2.6 23.6 – 2.2 0.49
HbA1c (%) 7.4 – 0.9 – –
Insulin dose
(units/kg/day)
0.83 – 0.17 – –
Retinopathy – – –
No retinopathy 15 cases (88%) – –
Simple retinopathy 2 cases (12%) – –
Urine albumin-to-
creatinine
ratio (mg/g
creatinine)
11.2 – 13.8 – –
Physical activity† Grade I: 2,
grade II: 8,
grade III: 7
Grade I: 1,
grade II: 15,
grade III: 2
0.07
Current smokers 6 cases (35.3%) 9 cases (50.0%) 0.38
Alcohol intake (g/day) 21.5 – 9.0 21.5 – 8.3 1
Data are shown as mean – standard deviation or n (%). †Grade I:
exercise every day; grade II: exercise twice or thrice a week; grade III:
no exercise. BMI, body mass index; HbA1c, glycated hemoglobin.
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Table 2 shows comparative data on biochemical markers in
patients with type 1 diabetes and controls. Serum levels of total
protein, albumin, calcium and magnesium were signiﬁcantly
lower in patients with type 1 diabetes than in controls. Serum
high-density lipoprotein cholesterol levels were signiﬁcantly
higher in patients with type 1 diabetes than in controls. Serum
low-density lipoprotein cholesterol levels tended to be lower in
patients with type 1 diabetes than in controls. The plasma level
of intact parathyroid hormone and serum levels of alkaline
phosphatase, total cholesterol and phosphorous did not signiﬁ-
cantly differ between the two groups. Serum IGF-1 and the
IGF-1 Z-score were signiﬁcantly lower in patients with type 1
diabetes than in controls (130.4 – 34.0 ng/mL vs 158.0 –
35.0 ng/mL, -1.2 – 0.74 vs -0.53 – 0.65, P < 0.05 and P <
0.01, respectively). Serum levels of bone metabolic markers were
comparable between the two groups.
Table 3 shows the vBMD and cross-sectional geometry of
the femoral neck, intertrochanter, and femoral shaft and the
vBMD of the lumbar spine in patients with type 1 diabetes and
controls. In the femoral neck, patients with type 1 diabetes had
a lower total vBMD (266.4 mg/cm3 vs 292.1 mg/cm3, P =
0.09), lower cortical thickness (3.0 mm vs 3.4 mm, P = 0.12)
and signiﬁcantly lower cortical vBMD compared with controls
(557.1 mg/cm3 vs 581.5 mg/cm3, P < 0.05). In the intertro-
chanter, patients with type 1 diabetes had a signiﬁcantly lower
total vBMD, cortical thickness and cortical CSA compared with
controls (222.7 mg/cm3 vs 258.5 mg/cm3, 2.8 mm vs 3.3 mm,
4.2 cm2 vs 5.2 cm2, respectively, all P < 0.01). In the femoral
shaft, patients with type 1 diabetes had a signiﬁcantly lower
cortical perimeter and cortical CSA compared to controls. The
vBMD of the lumbar spine (L2, 3, 4 and L2-4) was comparable
between the two groups.
Long disease duration (≥20 years) was not associated with
vBMD or cross-sectional geometry in the femoral bone subfrac-
tions or vBMD in the lumbar spine (Table S1). Type 1 diabetes
patients with low BMI (≤22.5 kg/m2) had signiﬁcantly lower
total BMD and higher BR in the intertrochanter than type 1
diabetes patients with high BMI (Table S2).
Table 2 | Serum biochemical markers and bone metabolic/quality
markers of type 1 diabetes patients and controls
Type 1 diabetes
patients (n = 17)
Controls
(n = 18)
P
Total protein (g/dL) 7.2 – 0.4 7.5 – 0.4 <0.05
Albumin (g/dL) 4.5 – 0.2 4.9 – 0.30 <0.01
ALP (U/L) 264.5 – 92.5 225.8 – 58.6 0.15
TC (mg/dL) 201.2 – 34.5 207.7 – 27.6 0.54
HDL-C (mg/dL) 67.7 – 18.3 53.6 – 9.3 <0.01
LDL-C (mg/dL) 108.8 – 22.0 123.0 – 24.0 0.08
Intact PTH (pg/mL) 35.9 – 14.7 35.5 – 11.0 0.93
Ca (mg/dL) 9.3 – 0.3 9.6 – 0.3 <0.01
Mg (mg/dL) 2.0 – 0.2 3.3 – 4.9 0.25
P (mg/dL) 3.5 – 0.8 3.5 – 0.6 0.94
Serum IGF-1 (ng/mL) 130.4 – 34.0 158.0 – 35.0 <0.05
IGF-1 Z-score -1.2 – 0.74 -0.53 – 0.65 <0.01
BAP (ug/L) 16.7 – 11.4 14.0 – 5.7 0.39
OC (ng/mL) 5.9 – 2.6 5.7 – 2.9 0.80
P1NP (ug/L) 42.7 – 37.0 47.1 – 19.2 0.67
TRACP-5b (mU/dL) 316.6 – 121.7 293.4 – 96.1 0.54
NTX (nmol BCE/L) 16.1 – 3.2 16.2 – 4.3 0.92
Pentosidine (ug/L) 0.04 – 0.01 0.04 – 0.01 0.58
Homocysteine (nmol/mL) 11.9 – 3.0 10.8 – 2.0 0.24
Data are shown as mean – standard deviation. ALP, alkaline phospha-
tase; BAP, bone specific alkaline phosphatase; HDL-C, high-density lipo-
protein cholesterol; IGF-1, insulin-like growth factor-1; LDL-C, low-density
lipoprotein cholesterol; OC, osteocalcin; NTX, cross-linked N-telopeptide
of type 1 collagen; P1PN, N-propeptide of type 1 collagen; PTH, para-
thyroid hormone; TC, total cholesterol; TRACP-5P, tartrate-resistant acid
phosphatase type5 protein.
Table 3 | Quantitative computed tomography measurements data of
type 1 diabetes patients and controls
Type 1 diabetes
patients
Controls P
Femoral neck n = 17 n = 18
Total vBMD (mg/cm3) 266.4 – 33.5 292.1 – 51.1 0.09
Cortical vBMD (mg/cm3) 557.1 – 31.8 581.5 – 27.6 <0.05
Cortical perimeter (cm) 10.3 – 1.5 10.9 – 1.4 0.23
Cortical thickness (mm) 3.0 – 0.6 3.4 – 0.9 0.12
Total CSA (cm2)　 9.9 – 1.2 9.7 – 1.1 0.57
Cortical CSA (cm2) 2.7 – 0.5 3.1 – 0.8 0.11
Inter trochanter n = 17 n = 18
Total vBMD (mg/cm3) 222.7 – 28.3 258.5 – 42.8 <0.01
Cortical vBMD (mg/cm3) 654.9 – 32.6 668.3 – 23.5 0.18
Cortical perimeter (cm) 16.0 – 0.64 16.4 – 1.0 0.18
Cortical thickness (mm) 2.8 – 0.4 3.3 – 0.6 <0.01
Total CSA (cm2)　 19.8 – 1.5 20.5 – 2.1 0.25
Cortical CSA (cm2) 4.2 – 0.6 5.2 – 1.1 <0.01
Femoral shaft n = 15 n = 10
Total vBMD (mg/cm3) 582.9 – 66.4 629.4 – 82.5 0.13
Cortical vBMD (mg/cm3) 965.2 – 65.6 981.0 – 57.3 0.54
Cortical perimeter (cm) 9.9 – 0.6 10.4 – 0.5 <0.05
Cortical thickness (mm) 5.8 – 0.5 6.5 – 1.1 0.08
Total CSA (cm2)　 8.9 – 3.2 8.8 – 0.8 0.86
Cortical CSA (cm2) 4.6 – 0.4 5.4 – 0.9 <0.05
Lumbar spine n = 17 n = 18
L2 vBMD (mg/cm3) 134.7 – 22.8 145 – 32.7 0.29
L3 vBMD (mg/cm3) 131.9 – 23.4 139.5 – 30.5 0.41
L4 vBMD (mg/cm3) 138.1 – 23.8 142.5 – 28.8 0.65
Total (L2-4) vBMD (mg/cm3) 134.9 – 23.0 142.2 – 30.4 0.42
Data are shown as mean – standard deviation. CSA, cross-sectional
area; vBMD, volumetric bone mineral density.
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Figure 1 shows biomechanical parameters of the femoral
neck, intertrochanter and femoral shaft in patients with type 1
diabetes and controls. In the femoral neck and femoral shaft,
the CMSI, SM and BR were comparable between the two
groups. In the intertrochanter, patients with type 1 diabetes
had a signiﬁcantly higher BR compared with controls
(12.9 – 1.9 vs 10.8 – 1.9, P < 0.01), but no signiﬁcant differ-
ence was found between the two groups in the CMSI or SM.
Table 4 shows simple correlations of serum IGF-1 values
with the QCT measurements in the femoral neck, intertro-
chanter and femoral shaft, and with the vBMD of the lumbar
spine. The serum IGF-1 values in patients with type 1 diabetes
correlated positively with the vBMD of the femoral neck and
lumbar spine, and tended to correlate with the cortical CSA of
the femoral neck and intertrochanter, but the relationships did
not reach statistical signiﬁcance. Serum IGF-1 values in patients
with type 1 diabetes tended to correlate negatively with the BR
of the femoral neck and intertrochanter.
We also measured 2-D BMD using QCT (CTXA-hip). The
2-D BMD values measured by QCT did not signiﬁcantly differ
between the patients with type 1 diabetes and controls in the
total hip and femoral neck (0.85 – 0.10 g/cm2 vs 0.97 –
0.17 g/cm2 and 0.74 – 0.10 g/cm2 vs 0.80 – 0.15 g/cm2, P =
0.07, P = 0.23, respectively).
DISCUSSION
The QCT ﬁndings in this cross-sectional case–control study
demonstrated cortical instability and lower vBMD, cortical
thickness, and cortical CSA in the intertrochanter of young and
middle-aged patients with type 1 diabetes.
Peripheral QCT has been the chief imaging modality for the
assessment of the vBMD at appendicular sites in pediatric and
adolescent patients with type 1 diabetes for several years19,20.
Peripheral QCT is preferred to central QCT, as the higher radia-
tion dose of the latter poses greater risk, especially to pediatric
patients21,29. The present report is the ﬁrst to determine bone
measurements of the lumbar spine and proximal femur by central
QCT in young and middle-aged patients with type 1 diabetes.
The vBMD of the proximal femur measured by QCT is
strongly predictive of hip fracture in both postmenopausal
women17,18,30 and older men15. Few reports, however, have
described the associations of vBMD with hip fracture in dia-
120
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Figure 1 | Biomechanical parameters of the femoral neck,
intertrochanter, and femoral shaft of type 1 diabetes patients and
controls. BR, buckling ratio; CMSI, cross-sectional moment of inertia; SM,
section modulus.
Table 4 | Simple correlations between serum insulin-like growth factor-
1 levels and quantitative computed tomography measurements.
Type 1 diabetes
patients
Controls
r P r P
Femoral neck n = 17 n = 18
Total vBMD (mg/cm3) 0.49 <0.05 0.13 0.59
Cortical vBMD (mg/cm3) -0.13 0.63 0.32 0.19
Cortical perimeter (cm) 0.06 0.82 -0.38 0.12
Cortical thickness (mm) 0.39 0.12 0.03 0.92
Total CSA (cm2)　 0.08 0.77 -0.09 0.72
Cortical CSA (cm2) 0.44 0.07 0.01 0.98
CSMI (cm4) -0.04 0.89 -0.13 0.62
SM (cm3) -0.03 0.9 -0.04 0.86
BR -0.44 0.08 -0.11 0.66
Intertrochanter n = 17 n = 18
Total vBMD (mg/cm3) 0.28 0.28 0.26 0.3
Cortical vBMD (mg/cm3) -0.25 0.33 0.34 0.16
Cortical perimeter (cm) -0.04 0.88 -0.16 0.53
Cortical thickness (mm) 0.39 0.12 0.19 0.46
Total CSA (cm2)　 0.04 0.88 -0.14 0.58
Cortical CSA (cm2) 0.36 0.16 0.05 0.83
CSMI (cm4) -0.07 0.78 -0.20 0.43
SM (cm3) -0.04 0.88 -0.17 0.51
BR -0.42 0.09 -0.21 0.39
Femoral shaft n = 15 n = 10
Total vBMD (mg/cm3) 0.26 0.34 -0.08 0.82
Cortical vBMD (mg/cm3) 0.13 0.65 -0.19 0.61
Cortical perimeter (cm) -0.04 0.89 0.35 0.32
Cortical thickness (mm) 0.35 0.2 0.03 0.93
Total CSA (cm2) 0.39 0.15 0.34 0.46
Cortical CSA (cm2) 0.18 0.52 0.15 0.68
CSMI (cm4) -0.19 0.5 0.34 0.34
SM (cm3) -0.19 0.51 0.35 0.32
BR -0.28 0.32 0.02 0.95
Lumbar spine total (L2-4) n = 17 n = 18
Total vBMD (mg/cm3) 0.60 <0.05 0.08 0.76
BR, buckling ratio; CSA, cross-sectional area; CSMI, cross-sectional
moment of inertia; SM, section modulus; vBMD, volumetric bone min-
eral density.
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betic patients. The bone geometry of the proximal femur
measured by QCT is thought to be strongly linked to bone
strength. According to a recent report from Ito et al.18, a lower
cortical CSA measured by QCT in the proximal femur is pre-
dictive of intertrochanteric fracture in elderly Japanese women.
CSA has proven to be a reliable estimator of compression
strength18. Several studies have shown associations linking fem-
oral neck fracture to a lower CSMI and SM, and higher BR of
the proximal femur18,30–32. The relationship of hip fractures
with the hip axis length and neck-shaft angle measured by
DXA scan has been investigated for years. A longer hip axis
length9,18 and wider neck-shaft angle33 were found to be associ-
ated with hip fracture independently of BMD in postmeno-
pausal women. Hip axis length and neck-shaft angle were
comparable between patients with type 1 diabetes and controls
in the present study (data not shown). Consensus has yet to be
reached on which structural features of the proximal femur are
most important as risk factors for fracture. Ample evidence has
shown, however, that proximal femurs with thinner walls tend
to buckle, regardless of the BMD9,12,13,18. Given this ﬁnding,
our present results suggest that a young or middle-aged patient
with type 1 diabetes with a lower vBMD, lower cortical CSA,
lower cortical thickness and higher BR of the intertrochanter
could face an elevated risk of intertrochanteric fracture in the
future.
The BR in patients with type 1 diabetes was signiﬁcantly
higher only in the intertrochanter compared with controls. This
stands to reason, as the cortical thickness differed between the
groups in the intertrochanter, but not in the femoral neck or
femoral shaft (see Table 3).
The total vBMD of the lumbar spine did not differ between
patients with type 1 diabetes and controls in the present study.
The lumbar spine is mainly composed of metabolically active
trabecular bone, and decreased BMD of the lumbar spine is
associated with poor metabolic control4,34,35. The relatively good
metabolic control in our participants (mean HbA1c 7.4%)
could explain the absence of any decrease in the total vBMD of
the lumbar spine in the present results.
Although the underlying mechanisms contributing to skeletal
deﬁcits in type 1 diabetes are poorly understood and probably
multifactorial, a consistent feature of type 1 diabetes, both in
humans and rodents, is a deﬁciency of insulin within the hepa-
tic portal circulation36. A lack of portal insulin is associated
with systemic deﬁciencies of IGF-1. Accumulating evidence sug-
gests that disturbed IGF-1 homeostasis in type 1 diabetes might
be responsible for the skeletal deﬁcits observed. Indeed, the
replacement of IGF-1 in rodent models of type 1 diabetes
results in signiﬁcant improvement in bone healing despite per-
sistent hyperglycemia37. In the present study, patients with
type 1 diabetes had signiﬁcantly lower IGF-1 values and IGF-1
Z-scores than controls. Furthermore, the serum IGF-1 values
were positively correlated with the total vBMD of the femoral
neck and lumbar spine in patients with type 1 diabetes, but not
in controls.
Previous studies of children and adolescents with type 1 dia-
betes have similarly shown positive associations between serum
IGF-1 values and bone mineral content measured by
DXA20,25,38.
A transgenic mouse model with speciﬁc IGF-1 gene inactiva-
tion in the liver manifested a reduction of the cortical CSA
associated with decreased periosteal circumference and weaker
bone determined by mechanical testing39. Meanwhile, Jiang
et al.40 observed a longer cortical width and increased cortical
CSA in transgenic mice with osteoblast-targeted IGF-1. Simi-
larly, the serum IGF-1 values in patients with type 1 diabetes
showed a weak positive association with the cortical CSA, and
a negative, less-than-signiﬁcant association with the BR in both
the femoral neck and intertrochanter (see Table 4). Serum IGF-
1 values could be indispensable for maintaining the cortical
CSA of the proximal femur in patients with type 1 diabetes.
Although both our results and previous studies37 show that
IGF-1 is more important in cortical bone than in trabecular
bone, serum IGF-1 values in patients with type 1 diabetes were
positively correlated with the total vBMD of the lumbar spine
containing a relatively higher proportion of trabecular bone in
the present study. Further studies will be required to show the
relationship between IGF-1 and cortical or trabecular bone
distribution.
Bone formation markers (bone-speciﬁc alkaline phosphatase,
N-propeptide of type I collagen and osteocalcin) were compara-
ble between patients with type 1 diabetes and controls, whereas
serum IGF-1 values were positively correlated with the serum
bone formation markers in patients with type 1 diabetes, but
not in controls (data not shown). Several earlier studies have also
found that IGF-1 values correlate positively with serum markers
of bone formation in patients with type 1 diabetes20,25,41.
The present study had several limitations requiring further
consideration. First, the study was a preliminary clinical study
with a cross-sectional design that precluded any revelations on
cause–effect relationships. Second, the relatively small sample in
the present study (n = 35 total) limited the precision of our
results. Larger studies will be required to more precisely charac-
terize the proximal femur geometry measured by QCT in
patients with type 1 diabetes. Third, we were unable to count
the numbers of patients with osteopenia and osteoporosis in the
present study, as no consensus standards have been developed
in Japan for assigning diagnostic categories for osteopenia and
osteoporosis based on measurements of spine BMD by QCT.
We conclude that QCT might be a useful tool for investigat-
ing the proximal femur geometry in patients with type 1 diabe-
tes. The present study is the ﬁrst investigation by QCT to show
cortical instability and lower vBMD in the intertrochanter of
young and middle-aged patients with type 1 diabetes. IGF-1
markedly inﬂuences the vBMD of the femoral neck and bone
formation in patients with type 1 diabetes.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Table S1 | Comparison of quantitative computed tomography measurements data between diabetes duration <20 years groups and
diabetes duration ≥20 years groups in type 1 diabetes patients.
Table S2 | Comparison of quantitative computed tomography measurements data between body mass index <22.5 kg/m2 groups
and body mass index ≥22.5 kg/m2 groups in type 1 diabetes patients.
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